secwatch.observer — SEC 8-K summary
======================================

Issuer:     Indaptus Therapeutics, Inc. (INDP)
CIK:        0001857044
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001493152-23-028054
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Indaptus Q2 2023 cash $19.7M, Phase 1 trial advances; CMO appointed
-------------------------------------------------------------------

- Cash and marketable securities $19.7M as of June 30, 2023; runway into Q2 2024.
- Phase 1 trial (Decoy20) completed first cohort, authorized to advance to second; evidence of immune activation.
- Appointed Roger Waltzman, M.D. as Chief Medical Officer, effective Aug 7, 2023.
- Q2 2023 net loss per share $0.39 vs $0.46 prior year; G&A down to $2.0M.
- Patent allowances in Brazil and India expanded IP protection to 32 countries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223028054/0001493152-23-028054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1857044/000149315223028054/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-028054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer